| 1 |
NCT01568307 |
Unknown † |
Major Depressive Disorder - Understanding The Link Between The Brain And The Heart |
- Major Depressive Disorder
|
- Drug: Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
|
Interventional |
Phase 4 |
- Baker IDI Heart and Diabetes Institute
- The Alfred
- Monash Medical Centre
- Ballarat Health Services
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of MDD patients carrying the s allele of the 5-HTT transporter that have higher sympathetic activity than homozygous ll patients.
- To determine the association between sympathetic activity and left ventricular hypertrophy.
- Change from baseline in the magnitude of morning surge in blood pressure.
- (and 2 more...)
|
80 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01568307 |
74/12
1022791 |
MDD |
May 2012 |
September 2014 |
December 2014 |
April 2, 2012 |
December 18, 2013 |
|
- Ballarat Health Service Psychiatric Services
Ballarat, Victoria, Australia - Monash Medical Centre - Monash Health
Clayton, Victoria, Australia - Alfred and Baker Medical Unit - Alfred Hospital
Melbourne, Victoria, Australia - Baker IDI Heart & Diabetes Institute
Melbourne, Victoria, Australia
|
| 2 |
NCT00296517 |
Completed
Has Results |
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors |
|
- Drug: 323U66 (Bupropion Hydrochloride Sustained Release)
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score
- Hamilton Depression Scale (HAM-D 17 Items) Total Score
- Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score at Week 8 and Total Score at Week 12
- (and 9 more...)
|
325 |
All |
18 Years to 65 Years (Adult) |
NCT00296517 |
AK1102365 |
|
January 19, 2006 |
March 1, 2008 |
March 28, 2008 |
February 27, 2006 |
May 22, 2017 |
July 16, 2009 |
- GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - (and 67 more...)
|
| 3 |
NCT03430869 |
Not yet recruiting |
Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK) |
- Major Depressive Disorder
|
- Drug: F-18 AV-45
- Drug: F-18-THK-5351
|
Interventional |
Phase 2 |
- Chang Gung Memorial Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The standard uptake value ratio (SUVR) of 18F-florbetapir
- The standard uptake value ratio (SUVR) of 18F-THK-5351
|
60 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT03430869 |
201601655A0 |
|
March 23, 2018 |
December 31, 2020 |
December 31, 2020 |
February 13, 2018 |
February 26, 2018 |
|
|
| 4 |
NCT02014363 |
Completed
Has Results |
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: ETS6103 (low dose)
- Drug: ETS6103 (high dose)
- Drug: Amitriptyline
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Baseline-adjusted (Montgomery-Asberg Depression Scale) MADRS Score at the End of Treatment.
|
164 |
All |
18 Years to 65 Years (Adult) |
NCT02014363 |
ETS6103-003
2013-000719-26 |
ETS6103-003 |
October 2013 |
October 2015 |
October 2015 |
December 18, 2013 |
January 11, 2017 |
January 11, 2017 |
- CPS Research
Glasgow, Scotland, United Kingdom
|
| 5 |
NCT00955474 |
Terminated
Has Results |
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms |
- Major Depressive Disorder With Psychotic Features
|
- Drug: Quetiapine
- Drug: escitalopram
- Drug: Sertraline
- Drug: Citalopram
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression
- Psychosis
- Fasting Blood Glucose
- (and 12 more...)
|
32 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00955474 |
2008P001022 |
Seroquel |
September 2008 |
January 2013 |
January 2013 |
August 10, 2009 |
April 20, 2017 |
March 28, 2016 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 6 |
NCT00168493 |
Unknown † |
The Neurobiology of Depressive Illness |
|
- Drug: antidepressants primarily selective serotonin reuptake inhibitors
|
Interventional |
Not Applicable |
- Baker Heart Research Institute
- National Health and Medical Research Council, Australia
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- level of sympathetic nervous system activity and its response to treatment
- clinical response to treatment
|
40 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT00168493 |
NHMRC D-01 |
|
June 2000 |
December 2008 |
December 2009 |
September 15, 2005 |
May 20, 2008 |
|
- Baker Heart Research Institute
Melbourne, Victoria, Australia
|
| 7 |
NCT00953745 |
Completed
Has Results |
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression |
- Major Depressive Disorder
|
- Drug: Escitalopram
- Drug: Aripiprazole
- Drug: Placebo Capsule
- Drug: Placebo Tablet
|
Interventional |
Not Applicable |
- Washington University School of Medicine
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders
- Depression Symptom Change on The Montgomery-Åsberg Depression Rating (MADRS) Scale Between ARP Responders and Non-responders.
|
43 |
All |
18 Years to 55 Years (Adult) |
NCT00953745 |
201101790-2 |
|
May 2009 |
June 2012 |
December 2012 |
August 6, 2009 |
April 19, 2018 |
April 19, 2018 |
- Washington University in St. Louis, School of Medicine
Saint Louis, Missouri, United States
|
| 8 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- ElMindA Ltd
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 9 |
NCT01175616 |
Withdrawn |
Creatine Augmentation in Veterans With SSRI-Resistant Major Depression |
- Major Depressive Disorder
|
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
- Changes in 3T 31Phosphorus Magnetic Resonance Spectroscopy metabolites
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT01175616 |
00041936 |
|
September 2012 |
April 2014 |
April 2014 |
August 5, 2010 |
August 15, 2016 |
|
|
| 10 |
NCT00229645 |
Completed |
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety |
- Major Depression With Comorbid Anxiety Symptoms
|
- Drug: Quetiapine Fumarate (Seroquel®)
|
Interventional |
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the
- 1. Hamilton Depression Scale (HAM-D) total score,
- 2. Hamilton Anxiety Scale (HAM-A) total score
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT00229645 |
D1441C00017 |
|
November 2003 |
|
April 2005 |
September 30, 2005 |
July 13, 2016 |
|
- Dr. A. McIntyre
Penticton, British Columbia, Canada
|
| 11 |
NCT01106313 |
Completed |
Insulin Resistance in Patients With Major Depression |
- Depression
- Bipolar Disorder
- Mood Disorders
- (and 3 more...)
|
|
Observational |
|
- Stanford University
- American Diabetes Association
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- To quantify insulin-mediated glucose uptake as assessed by the SSPG concentration in patients with depression and compare the values to those previously obtained in a healthy age-matched control population
- To examine the association between insulin resistance and cognitive performance and clinical course of depression in patients with depression
|
57 |
All |
20 Years to 65 Years (Adult) |
NCT01106313 |
SU-02172010-5003
eProtocol 17089 |
|
July 2009 |
January 2016 |
January 2016 |
April 19, 2010 |
October 4, 2017 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
| 12 |
NCT02049385 |
Terminated
Has Results |
Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression? |
|
- Drug: Diazoxide
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT02049385 |
140041
14-M-0041 |
|
January 3, 2014 |
July 21, 2016 |
July 21, 2016 |
January 30, 2014 |
October 13, 2017 |
October 13, 2017 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 13 |
NCT01197508 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder. |
- Major Depressive Disorder
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional |
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 19 more...)
|
696 |
All |
18 Years to 65 Years (Adult) |
NCT01197508 |
D4130C00005 |
|
September 2010 |
January 2012 |
January 2012 |
September 9, 2010 |
April 11, 2014 |
October 29, 2012 |
- Research Site
Buenos Aires, Caba, Argentina - Research Site
Ciudad Autonoma Bs As, Cba, Argentina - Research Site
Dublin, Argentina - (and 84 more...)
|
| 14 |
NCT01282632 |
Completed |
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression |
- Subjects Had Unipolar, Non-psychotic Major Depression
|
- Drug: Risperidone
- Drug: Olanzapine
|
Interventional |
Phase 1
Phase 2 |
- Sunnybrook Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Depression Rating Scale at 1 week
- Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 1 week
- Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 1 week
- (and 17 more...)
|
42 |
All |
18 Years to 65 Years (Adult) |
NCT01282632 |
ro123 |
|
August 2002 |
March 2004 |
March 2004 |
January 25, 2011 |
January 25, 2011 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
| 15 |
NCT01180400 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
- Major Depressive Disorder
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional |
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 18 more...)
|
295 |
All |
18 Years to 65 Years (Adult) |
NCT01180400 |
D4130C00003 |
|
September 2010 |
September 2011 |
September 2011 |
August 12, 2010 |
April 11, 2014 |
November 20, 2012 |
- Research Site
Brno, Czech Republic - Research Site
Kutna Hora, Czech Republic - Research Site
Litomerice, Czech Republic - (and 67 more...)
|
| 16 |
NCT01157078 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional |
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 19 more...)
|
319 |
All |
18 Years to 65 Years (Adult) |
NCT01157078 |
D4130C00002 |
|
June 2010 |
November 2011 |
November 2011 |
July 5, 2010 |
April 11, 2014 |
November 20, 2012 |
- Research Site
Tuscaloosa, Alabama, United States - Research Site
Tucson, Arizona, United States - Research Site
Little Rock, Arkansas, United States - (and 48 more...)
|
| 17 |
NCT03026309 |
Not yet recruiting |
PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F] FDOPA) uptake rate constant (K(i)) that reflects L-dopa transport.
|
60 |
Male |
30 Years to 50 Years (Adult) |
NCT03026309 |
0112-16-ASMC |
|
March 2017 |
March 2019 |
March 2019 |
January 20, 2017 |
January 20, 2017 |
|
|
| 18 |
NCT02134808 |
Active, not recruiting |
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Creatine
- Drug: Placebo
|
Interventional |
Phase 4 |
- Perry Renshaw
- University of Utah
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Brain phosphocreatine (PCr) concentrations
- Children's Depression Rating Scale-Revised (CDRS-R); Montgomery-Asberg Depression Rating Scale (MADRS)
|
71 |
Female |
12 Years to 21 Years (Child, Adult) |
NCT02134808 |
00073442 |
|
March 15, 2017 |
February 2021 |
February 2021 |
May 9, 2014 |
December 7, 2017 |
|
- University of Utah School of Medicine
Salt Lake City, Utah, United States
|
| 19 |
NCT00955955 |
Completed
Has Results |
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder |
|
- Other: 6(S)-5-MTHF(Deplin)
- Other: Placebo
|
Interventional |
Phase 4 |
- George I. Papakostas
- Pamlab, L.L.C.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The 17-item Hamilton Depression Scale (HAM-D-17)
- The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
|
75 |
All |
18 Years to 65 Years (Adult) |
NCT00955955 |
2006P000604 (2) |
TRD-2 |
July 2009 |
April 2011 |
April 2011 |
August 10, 2009 |
April 28, 2017 |
January 18, 2013 |
- University of California San Diego School of Medicine
San Diego, California, United States - Rush University Medical Center, Psychiatric Medicine Associates, LLC
Chicago, Illinois, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 3 more...)
|
| 20 |
NCT01114334 |
Completed
Has Results |
Motivational Interviews for Depression in Primary Care |
|
- Behavioral: Guideline-Based Medical Management
- Behavioral: Motivational Interviewing for Depression
|
Interventional |
Not Applicable |
- Denver Health and Hospital Authority
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Depression Remission
- Adherence to Treatment With Antidepressant Medication
- Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms
|
168 |
All |
18 Years and older (Adult, Senior) |
NCT01114334 |
K23MH082997 |
|
April 2010 |
December 2012 |
December 2012 |
May 3, 2010 |
April 20, 2017 |
April 20, 2017 |
- Denver Health and Hospital Authority
Denver, Colorado, United States
|
| 21 |
NCT01454635 |
Completed |
Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression
|
96 |
All |
20 Years and older (Adult, Senior) |
NCT01454635 |
SU-GEC-84 |
AFADTRMDD |
June 2008 |
March 2010 |
March 2010 |
October 19, 2011 |
October 31, 2011 |
|
- Showa University Northern Yokohama Hospital
Yokohama, Kanagawa, Japan
|
| 22 |
NCT00049972 |
Completed |
Major Depressive Disorder Study In Adults |
- Major Depressive Disorder
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of patients who prematurely terminated treatment due to treatment emergent adverse events
- Recurrence rates of adverse events causing intolerability of previous SSRI/SNRI, Adverse event incidence rates, Mean change from baseline in the Beck Depression Inventory-II total score, Proportion of responsers based on teh CGI Global Improvement Item
|
646 |
All |
18 Years and older (Adult, Senior) |
NCT00049972 |
SB29060.833 |
|
September 2002 |
September 2003 |
September 2003 |
November 19, 2002 |
September 11, 2017 |
|
- GSK Clinical Trial Call Center
Birmingham, Alabama, United States - GSK Clinical Trial Call Center
Birmingham, Alabama, United States - GSK Clinical Trial Call Center
Fairfield, Alabama, United States - (and 68 more...)
|
| 23 |
NCT01370499 |
Completed |
A Study of LY2216684 in Patients With Major Depression Disorder |
- Major Depressive Disorder
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with clinically significant events
- Number of participants with suicidal behaviors and ideations measured by the Columbia-Suicide Severity Rating Scale (CSSRS)
- Change from baseline to 52 week endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) total score and individual items
- (and 8 more...)
|
237 |
All |
18 Years and older (Adult, Senior) |
NCT01370499 |
12849
H9P-JE-LNDJ |
|
August 2011 |
January 2014 |
January 2014 |
June 10, 2011 |
May 6, 2014 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chiba, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukuoka, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukushima, Japan - (and 6 more...)
|
| 24 |
NCT01153347 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
- Major Depressive Disorder
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional |
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 20 more...)
|
2409 |
All |
18 Years to 65 Years (Adult) |
NCT01153347 |
D4130C00004 |
|
June 2010 |
January 2012 |
January 2012 |
June 30, 2010 |
April 11, 2014 |
November 20, 2012 |
- Research Site
Birmingham, Alabama, United States - Research Site
Tucson, Arizona, United States - Research Site
Conway, Arkansas, United States - (and 96 more...)
|
| 25 |
NCT00321152 |
Completed |
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Other: 6(S)-5-MTHF (a Medical Food)
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Pamlab, L.L.C.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
150 |
All |
18 Years to 65 Years (Adult) |
NCT00321152 |
2006P000604 |
|
November 2006 |
August 2008 |
June 2010 |
May 3, 2006 |
June 8, 2010 |
|
- University of California San Diego School of Medicine
San Diego, California, United States - Rush University Medical Center, Psychiatric Medicine Associates, LLC
Chicago, Illinois, United States - Lousiana State University Health Sciences Center
New Orleans, Louisiana, United States - (and 8 more...)
|
| 26 |
NCT00873795 |
Completed |
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression |
- Major Depressive Disorder
|
- Drug: aripiprazole , sertraline
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- score change of Hamilton Rating Scale For Depression (HAM-D17 )
- score change of Brief Psychiatric Rating Scale (BPRS-50)
|
41 |
All |
18 Years to 65 Years (Adult) |
NCT00873795 |
IRB 09603-001 |
|
April 2007 |
March 2009 |
March 2009 |
April 2, 2009 |
April 2, 2009 |
|
- Psychiatry Department, Chimei Medical Center
Tainan, Taiwan
|
| 27 |
NCT01962753 |
Recruiting |
Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP) |
|
|
Interventional |
Not Applicable |
- University Hospital, Tours
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- standards uptakes values (SUVr)
- Residual cognitive deficits
|
150 |
All |
55 Years and older (Adult, Senior) |
NCT01962753 |
PHRN10-VC/ ASAP |
ASAP |
May 2012 |
May 2018 |
May 2018 |
October 14, 2013 |
February 16, 2015 |
|
- University Hospital of Besançon- Jean Minjoz
Besançon, France - University Hospital of Caen
Caen, France - University Hospital of Lille
Lille, France - (and 6 more...)
|
| 28 |
NCT00633399 |
Completed
Has Results |
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs |
- Major Depressive Disorder
|
- Drug: Ziprasidone
- Drug: Placebo
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- University of Alabama at Birmingham
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2
- Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.
- Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8
|
458 |
All |
18 Years to 65 Years (Adult) |
NCT00633399 |
2007-P-002361 |
|
July 2008 |
March 2014 |
March 2014 |
March 12, 2008 |
July 3, 2014 |
July 3, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Massachusetts General Hospital- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 29 |
NCT01185340 |
Completed |
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline to week 11 in Montgomery-Asberg Depression Rating Scale (MADRS) total score
- Change from baseline to week 11 in Sheehan Disability Scale (SDS) Global Functional Impairment scale
- Change from baseline to week 11 in Fatigue Associated with Depression (FAsD) impact subscale score
- (and 16 more...)
|
793 |
All |
18 Years and older (Adult, Senior) |
NCT01185340 |
12183
H9P-MC-LNBR |
|
March 2011 |
April 2013 |
April 2013 |
August 19, 2010 |
September 27, 2013 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Garden Grove, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Oakland, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Temecula, California, United States - (and 46 more...)
|
| 30 |
NCT00556140 |
Completed
Has Results |
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression |
|
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Depression and Psychosis Response Rate
- Depression and Psychosis Remission Rate
|
16 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00556140 |
2003-P-000990 |
Abilify |
June 2003 |
January 2008 |
January 2008 |
November 9, 2007 |
August 20, 2012 |
August 20, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 31 |
NCT02805439 |
Completed |
Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment |
- Major Depressive Disorder
|
- Drug: S47445 15mg
- Drug: S47445 50mg
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAM-D) total score expressed as change from baseline value
- HAM-D total score
- Response to treatment defined by HAM-D total score decrease from baseline ≥ 50%
- (and 10 more...)
|
400 |
All |
18 Years to 65 Years (Adult) |
NCT02805439 |
CL2-47445-014
2015-003867-13 |
|
March 2016 |
April 2017 |
April 2017 |
June 20, 2016 |
April 24, 2018 |
|
- Mental Health Centre - Plovdiv
Plovdiv, Bulgaria - Mental Health Centre - Sofia district
Sofia, Bulgaria - Military Medical Academy, MHAT - Sofia
Sofia, Bulgaria - (and 50 more...)
|
| 32 |
NCT00086307 |
Completed
Has Results |
Lexapro and Pramipexole and to Treat Major Depression |
|
- Drug: Pramipexole
- Drug: Escitalopram
|
Interventional |
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale (MADRS)
|
39 |
All |
18 Years to 65 Years (Adult) |
NCT00086307 |
040227
04-M-0227 |
|
June 2004 |
March 2010 |
March 2010 |
June 30, 2004 |
January 28, 2013 |
July 12, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 33 |
NCT00840034 |
Completed
Has Results |
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: LY2216684
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to 8 Weeks in Montgomery-Asberg Depression Rating Scale (MADRS)
- Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Total Score
- Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Individual Items
- (and 10 more...)
|
227 |
All |
18 Years to 65 Years (Adult) |
NCT00840034 |
12850
H9P-MC-LNDK |
|
February 2009 |
January 2010 |
January 2010 |
February 10, 2009 |
April 24, 2018 |
April 24, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Little Rock, Arkansas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Carson, California, United States - (and 21 more...)
|
| 34 |
NCT01152554 |
Completed
Has Results |
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
- Major Depressive Disorder
- MDD
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional |
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of Patients Experiencing at Least One Adverse Event (AE)
- Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)
- Frequency of Patients Experiencing Serious Adverse Events (SAEs)
- (and 6 more...)
|
813 |
All |
18 Years to 65 Years (Adult) |
NCT01152554 |
D4130C00007 |
|
June 2010 |
February 2012 |
February 2012 |
June 29, 2010 |
April 11, 2014 |
October 29, 2012 |
- Research Site
Birmingham, Alabama, United States - Research Site
Tuscaloosa, Alabama, United States - Research Site
Tucson, Arizona, United States - (and 91 more...)
|
| 35 |
NCT00157547 |
Completed |
Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression |
- Major Depressive Disorder
|
- Drug: Selective serotonin reuptake inhibitors (SSRI)
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Medtronic - MITG
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
95 |
All |
18 Years to 65 Years (Adult) |
NCT00157547 |
2002-P-001784 |
|
April 2003 |
August 2006 |
August 2006 |
September 12, 2005 |
May 28, 2008 |
|
|
| 36 |
NCT01173601 |
Completed
Has Results |
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Scale
- Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score
- (and 18 more...)
|
1416 |
All |
18 Years and older (Adult, Senior) |
NCT01173601 |
11316
H9P-MC-LNBM |
|
November 2010 |
October 2013 |
October 2013 |
August 2, 2010 |
April 17, 2018 |
April 17, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Irvine, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
La Habra, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Redlands, California, United States - (and 60 more...)
|
| 37 |
NCT01221935 |
Completed |
Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Other: Pristiq first-line treatment charts
- Other: Pristiq second-line treatment charts
- Other: SNRI or SSRI first-line treatment charts
- Other: SNRI or SSRI second-line treatment charts
|
Observational |
|
|
Industry |
- Time Perspective: Retrospective
|
- 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment.
- 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI).
- 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment.
- (and 6 more...)
|
2701 |
All |
18 Years and older (Adult, Senior) |
NCT01221935 |
3151A1-4431
B2061039 |
|
September 2009 |
January 2010 |
January 2010 |
October 18, 2010 |
January 26, 2011 |
|
|
| 38 |
NCT00733668 |
Completed |
Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Quetiapine fumarate (Seroquel)
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Montgomery-Asberg Depression Scale (MADRS) score
- The Brief psychiatric Rating Scale (BPRS) scoreThe Clinical Global impression (CGI) scorePatient reported outcomes (PROs)
- Sheehan Disability Scale (SDS) score
- The Symptom Checklist 90 Revisred (SCL-90-R) score
|
|
All |
18 Years to 65 Years (Adult) |
NCT00733668 |
D1449C00009 |
UNIQUE |
March 2006 |
November 2007 |
November 2007 |
August 13, 2008 |
March 25, 2009 |
|
- Research Site
Brugge, Belgium - Research Site
Leuven, Belgium - Research Site
Liege, Belgium - Research Site
Sint-Truiden, Belgium
|
| 39 |
NCT01187407 |
Completed
Has Results |
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment |
- Major Depressive Disorder (MDD)
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change From Randomization to Week 8 in the Sheehan Disability Scale (SDS) Global Functional Impairment Score
- Change From Randomization to Week 8 in the Fatigue Associated With Depression (FAsD) Impact Subscale Score
- (and 17 more...)
|
1480 |
All |
18 Years and older (Adult, Senior) |
NCT01187407 |
12182
H9P-MC-LNBQ |
|
March 2011 |
August 2013 |
August 2013 |
August 24, 2010 |
April 24, 2018 |
April 24, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chino, California, United States - (and 51 more...)
|
| 40 |
NCT00043550 |
Completed
Has Results |
Treatments for Depression: Drug Versus Psychotherapy |
|
- Behavioral: Supportive Expressive Therapy
- Drug: Sertraline
- Drug: Pill Placebo
- Drug: Venlafaxine
|
Interventional |
Phase 3 |
- University of Pennsylvania
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression-17 Item
|
156 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00043550 |
R01MH061410
DSIR 83-ATAS |
|
November 2001 |
June 2009 |
June 2009 |
August 12, 2002 |
June 2, 2017 |
June 2, 2017 |
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 41 |
NCT01299272 |
Completed
Has Results |
A Study in Prevention of Re-emergence of Depression Symptoms |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period)
- Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period)
- Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period)
- (and 26 more...)
|
1249 |
All |
18 Years and older (Adult, Senior) |
NCT01299272 |
11317
H9P-MC-LNBN |
|
May 2011 |
November 2013 |
November 2013 |
February 18, 2011 |
April 17, 2018 |
April 17, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Redlands, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sherman Oaks, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wildomar, California, United States - (and 74 more...)
|
| 42 |
NCT00812812 |
Terminated
Has Results |
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study) |
|
- Drug: paroxetine 10mg tablet
- Drug: paroxetine 20mg tablet
- Drug: matched placebo to paroxetine 10mg
- Drug: matched placebo to paroxetine 20mg
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8
- Change From Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6
- Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8
- (and 2 more...)
|
56 |
All |
7 Years to 17 Years (Child) |
NCT00812812 |
112487 |
|
March 2009 |
February 2011 |
February 2011 |
December 22, 2008 |
January 13, 2017 |
October 13, 2011 |
- GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - (and 30 more...)
|
| 43 |
NCT02720198 |
Recruiting |
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD |
- Major Depressive Disorder
|
- Drug: Levomilnacipran
- Drug: Quetiapine
|
Interventional |
Phase 3 |
- Duke University
- Forest Laboratories
- Institute for Advanced Medical Research, Alpharetta, GA
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) total score
- Response Rate
- Remission Rate
- (and 8 more...)
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT02720198 |
Pro00064983 |
|
January 23, 2017 |
August 2018 |
September 2018 |
March 25, 2016 |
May 10, 2017 |
|
- Institute for Advanced Medical Research
Alpharetta, Georgia, United States
|
| 44 |
NCT02969876 |
Recruiting |
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine |
- Depressive Disorder
- Major Depression
- Depression
- Depression, Unipolar
|
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Takeda
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Mnemonic Similarity Task
- Brain Derived Neurotrophic Factors Levels in the Blood
- Quick Inventory of Depressive Symptomatology
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult) |
NCT02969876 |
2016P001243 |
VOR-IISR |
November 2016 |
November 2017 |
November 2017 |
November 21, 2016 |
November 21, 2016 |
|
- the Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 45 |
NCT00000378 |
Completed
Has Results |
Antidepressant Treatment of Melancholia in Late Life |
|
- Drug: Sertraline
- Drug: Nortriptyline
|
Interventional |
Phase 4 |
- New York State Psychiatric Institute
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HAMILTON Rating Scale for DEPRESSION Range
|
110 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT00000378 |
#3105
R01MH055716 |
|
July 1997 |
June 2002 |
June 2002 |
November 3, 1999 |
October 7, 2015 |
April 21, 2015 |
- 1051 Riverside Drive
New York, New York, United States
|
| 46 |
NCT00361218 |
Completed
Has Results |
Biological Markers of Response to Treatment in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: open-label selective serotonin reuptake inhibitor (SSRI)
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Brain-derived Neurotrophic Factor (BDNF) Levels
- Quantitative Electroencephalogram Measurements
|
72 |
All |
18 Years to 65 Years (Adult) |
NCT00361218 |
2005P000413 |
|
October 2005 |
December 2008 |
December 2008 |
August 8, 2006 |
November 21, 2017 |
September 26, 2013 |
|
| 47 |
NCT02307617 |
Recruiting |
Glutamate Probes in Adolescent Depression |
- Major Depressive Disorder
- Major Depressive Disorder, Recurrent
- Major Depressive Disorder, Remitted
|
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- Concentrations of GABA and glutamate in the brains of adolescents with MDD.
- The change of GABA and glutamate concentrations in adolescents with MDD after 6 weeks of SSRI treatment.
- The effect of glutamatergic and GABAergic functioning on human development in adolescents with MDD
- The effect of glutamatergic and GABAergic functioning on human development in adolescents with MDD after 6 weeks of SSRI treatment.
|
100 |
All |
13 Years to 21 Years (Child, Adult) |
NCT02307617 |
14-004662 |
GPII |
August 1, 2014 |
December 31, 2018 |
March 31, 2019 |
December 4, 2014 |
October 19, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 48 |
NCT02434393 |
Active, not recruiting |
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project |
- Major Depression
- Late Life Depression (LLD)
|
|
Observational |
|
- University of Southern California
- National Institute of Mental Health (NIMH)
- University of California, San Francisco
- Alzheimer's Therapeutic Research Institute
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct.
- Rate of Change in expressive language as measured by the Boston Naming Test using total correct.
- Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.
- (and 3 more...)
|
133 |
All |
65 Years and older (Adult, Senior) |
NCT02434393 |
ADC-048
R01MH098062 |
ADNI-D |
March 4, 2015 |
January 2020 |
January 2021 |
May 5, 2015 |
December 8, 2017 |
|
- University of California, San Francisco
San Francisco, California, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
| 49 |
NCT00993876 |
Completed |
Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment |
- Cognitive Performance in Major Depression
|
- Drug: citalopram
- Drug: reboxetine
- Behavioral: interpersonal psychotherapy
|
Interventional |
Not Applicable |
- Zentrum für Integrative Psychiatrie
- German Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- cognitive performance with respect to cognitive flexibility, memory and attention
- CREB-phosphorylation in T-Lymphocytes
|
45 |
All |
20 Years to 45 Years (Adult) |
NCT00993876 |
KO 2067 |
Decoflex |
August 2005 |
August 2008 |
August 2008 |
October 14, 2009 |
October 14, 2009 |
|
- Zentrum für Integrative Psychiatrie
Kiel, Germany
|
| 50 |
NCT02972398 |
Recruiting |
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders |
- Major Depressive Disorders
|
- Drug: N-acetylcysteine
- Drug: placebo comparator of N-acetylcysteine
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The change from baseline Hamilton Depression Rating Scale (HAMD)-17 items at week2,4,6,8,10,and 12.
- The change from baseline HAMD-17 items at week14,16,18,and 20.
- The effects of augmentation treatment with NAC on scores in Beck Anxiety Inventory (BAI)
- (and 6 more...)
|
200 |
All |
18 Years to 65 Years (Adult) |
NCT02972398 |
NAC-2015-TJAH |
|
September 2015 |
September 2018 |
March 2019 |
November 23, 2016 |
April 25, 2018 |
|
- Tianjin Anding Hospital
Tianjin, Tianjin, China
|
Create an RSS feed from your search for:
Download the search results for: